This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.
Mailbox Ctrc Regulatory Affairs
regaffapp@uthscsa.edu
Principal Investigator
Andrew Brenner
Frances Crawford
(210) 450-5037
crawfordf1@uthscsa.edu
Sonia Creighton
(210) 450-1366
creighton@uthscsa.edu
Myrna Montenegro
(210) 450-5954
montenegro@uthscsa.edu
Courtney Nichols
(210) 450-1794
nicholsc2@uthscsa.edu
Mailbox Ctrc Regulatory Affairs
regaffapp@uthscsa.edu
Regulatory Staff
regaffstaff@uthscsa.edu
Kathleen Rodriguez
(210) 450-1365
rodriguezk3@uthscsa.edu
Benjamin Schleif
(210) 450-1366
schleifb@uthscsa.edu
Morgan Seekatz
(210) 450-1133
seekatz@uthscsa.edu
Histologically proven intracranial glioblastoma or gliosarcoma at initial surgery
Patients must be able to tolerate brain MRI scans with dynamic intravenous gadolinium-based contrast agent injections
No contraindication to intravenous contrast administration
Arm | Description | Intervention |
---|---|---|
Diagnostic (DSC-MRI) | Patients undergo DSC-MRI within 3 days before bevacizumab initiation and at day 15. | Undergo DSC-MRI Other names:
|